Saniona beviljas ny särläkemedelsstatus för Tesomet av FDA för patienter med hypotalamisk fetma.
Kontraktstillverkaren Hanza levererade rekordhög lönsamhet under andra kvartalet trots att knappt en...
Redeye is growing somewhat more confident in the case as OXE Marine sees continued good progress in ...
Starkt resultat i Q2'21 Bergs Timber levererade omsättning på 826 mkr i Q2'21, motsvarande en tillväxt på 52% y/y, samt EBITDA på 146 mkr (5...
Q1 started off rather slow Detection Technology will report its Q2 results next Tuesday on August 3r...
Significant earnings growth also beyond the pandemic We believe that CTT is on track to recover from...
Service standing out in Q2 EBIT beat of 12% Q2 was characterized by a return to normalcy with organic growth of 51%, compared to a quarter s...
Q2 results Market activity is improving, especially in ports.
Q2 EBITDA was SEK 146m, higher prices and volumes Q2 was a very strong quarter for Bergs Timber.
Key takes from the Q2’21 report Swedencare’s Q2’21 report was strong, although the company continues to see supply chain issues.
Redeye leaves a comment on Xspray following the announcement that its HyNap-Dasa 505(b)(2) reached b...
Q3 was slightly mixed, with a strong top line driven by still-high student/child intake (+15.
Organic growth has likely been healthy and we forecast 8.
Lägre försäljning i USA sänkte lönsamheten i Q2 Probis omsättning i Q2 2021 minskade 3% valutajuster...
Redeye ser med spänning fram emot det kommande året då Arise kommer ta de första stegen på sin nya t...
Redeye raises its Base case for Vertiseit following its Q2 report, despite a mixed outcome.
Mangold inleder bevakning av Brilliant Future med rekommendationen Köp och riktkursen 20,50 kronor p...
Q2 sales of SEK 154m, up 24.8% y-o-y (~2% organic) Invisio reported Q1’21 net sales of SEK 154m, +1.
VEF’s 30%+ NAV CAGR track record and improved ESG assessment have become increasingly credited by the investment community as its discount t...
Q2 details Q2'21 report: Net sales SEK 160m (-2% vs ABGSC 163m and -2% vs cons 163m), EBITDA SEK 47m...
Slight sales miss, but profitability in line Eltel delivered weaker sales than expected at EUR 210m ...
Redeye sees an overall solid Q2 report, with robust ARR growth and a pickup in new sales.
Urstarkt kvartal Rapporten för Q2 2021 slog våra och marknadens förväntningar med råge.
Redeye is still hopeful about Bong’s recovery and prospects for sustainable profitability, mainly dr...
Redeye raises its Base case and forecasts following a solid Q2 report, showing significant margin improvements.
We have previously thought that the Tier-1 card manufacturers would primarily go with their own solu...
The 2.1% operative EBITA margin met our estimate Q2 revenue declined by 14% y/y to EUR 210m, vs the ...
Förvärvet av Riaktr stärker i synnerhet SDS:s Business Intelligence-erbjudande och ger därtill tillgång till en ökad kundbas, däribland tele...
Redeye argues that the orphan drug designation is another progress and milestone for the company.
Q2’21e preview Swedencare will report its Q2’21 results on Thursday, 29 July.
